CISS vs ABEO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABEO Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Abeona Therapeutics Inc. Common Stock (ABEO) driven by superior Valuation, Options & Structure while CISS counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, CISS trades at N/M Forward P/E with 24.6% operating margin (+249.0% YoY revenue) versus ABEO at 18.7x Forward P/E and -186.1% operating margin (+2745.0% YoY). In options structure, CISS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against ABEO sits in BREAKDOWN (27th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CISS Revenue | ABEO Revenue | CISS Op. Margin | ABEO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | N/A | $0M | N/A | -3325.7% | ABEO |
| FY2018 | N/A | $0M | N/A | -1940.2% | ABEO |
| FY2020 | N/A | $10M | N/A | -814.2% | ABEO |
| FY2021 | N/A | $0M | N/A | -2994.5% | ABEO |
| FY2022 | N/A | $0M | N/A | -3600.8% | ABEO |
| FY2023 | $30M | $0M | 36.3% | -1346.7% | CISS |
| FY2024 | $40M | N/A | 23.8% | N/A | CISS |
| FY2025 | $30M | $10M | 3.9% | -1536.9% | CISS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CISS | ABEO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $991,199 | $167.4M | Larger Scale | ABEO |
| Trailing P/E Ratio Valuation | N/M | 18.7x | Lower Multiple | ABEO |
| Forward P/E Ratio Valuation | N/M | 18.7x | Lower Multiple | ABEO |
| Revenue Growth (YoY) Growth | +249.0% | +2745.0% | Higher Growth | ABEO |
| Operating Margin (TTM) Profitability | 24.6% | -186.1% | Higher Margin | CISS |
| Net Profit Margin Profitability | 27.4% | -160.3% | Higher Margin | CISS |
| Return on Equity (ROE) Capital Efficiency | 17.1% | -42.1% | Higher ROE | CISS |
| 52-Week Range Position Momentum | 20% ($0โ$6) | 6% ($2โ$8) | Stronger Trend | CISS |
| Beta / 30D Volatility Risk Regime | 11.91ฮฒ ยท 1054% Vol | 0.60ฮฒ ยท 149% Vol | Lower Realized Risk | ABEO |
| Unified Institutional Score Composite Signal | 33.6 / 100 (SELL) | 49.9 / 100 (HOLD) | Higher Composite | ABEO |